Elon Musk has reportedly indicated that X, previously known as Twitter, might become unavailable in Europe to bypass new EU regulations.
Elon Musk has reportedly indicated that X, previously known as Twitter, might become unavailable in Europe to bypass new EU regulations.
Twitter Inc (NYSE: TWTR) has warned that it might instigate legal proceedings against its competitor, Meta Platforms Inc (NASDAQ: FB), due to the striking similarities between their new app, Threads,
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the
Activation of First Clinical Trial Site in the U.S
While it may have initially been modelled as a microblogging platform, Twitter has, over time, become a place for traders to look out for trends in the stock market and
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO) announced that the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208) now includes information about its trial that assesses the safety and effectiveness of OK-101
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO),— an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to